Natural Products As a Means of Overcoming Cisplatin Chemoresistance in Bladder Cancer

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582013

Authors

Ganeshkumar Rajendran

John A Taylor 3rd

Benjamin L Woolbright

Affiliations

Soon will be listed here.

Abstract

Cisplatin remains an integral part of the treatment for muscle invasive bladder cancer. A large number of patients do not respond to cisplatin-based chemotherapy and efficacious salvage regimens are limited. Immunotherapy has offered a second line of treatment; however, only approximately 20% of patients respond, and molecular subtyping of tumors indicates there may be significant overlap in those patients that respond to cisplatin and those patients that respond to immunotherapy. As such, restoring sensitivity to cisplatin remains a major hurdle to improving patient care. One potential source of compounds for enhancing cisplatin is naturally derived bioactive products such as phytochemicals, flavonoids and others. These compounds can activate a diverse array of different pathways, many of which can directly promote or inhibit cisplatin sensitivity. The purpose of this review is to understand current drug development in the area of natural products and to assess how these compounds may enhance cisplatin treatment in bladder cancer patients.

Citing Articles

Nanocurcumin preserves kidney function and haematology parameters in DMBA-induced ovarian cancer treated with cisplatin via its antioxidative and anti-inflammatory effect in rats.

Louisa M, Wanafri E, Arozal W, Sandhiutami N, Basalamah A Pharm Biol. 2023; 61(1):298-305.

PMID: 36708211 PMC: 9888479. DOI: 10.1080/13880209.2023.2166965.

Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.

Noriega-Rivera R, Rivera-Serrano M, Rabelo-Fernandez R, Perez-Santiago J, Valiyeva F, Vivas-Mejia P Int J Mol Sci. 2022; 23(14).

PMID: 35887085 PMC: 9318856. DOI: 10.3390/ijms23147737.

Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?.

Ruiz de Porras V Cancer Drug Resist. 2022; 5(2):339-343.

PMID: 35800376 PMC: 9255239. DOI: 10.20517/cdr.2022.02.

Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them.

Ramos A, Sadeghi S, Tabatabaeian H Int J Mol Sci. 2021; 22(17).

PMID: 34502361 PMC: 8430957. DOI: 10.3390/ijms22179451.

References

McConkey D, Choi W, Shen Y, Lee I, Porten S, Matin S . A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin,.... Eur Urol. 2015; 69(5):855-62. PMC: 4775435. DOI: 10.1016/j.eururo.2015.08.034. View

Woods D, Turchi J . Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther. 2013; 14(5):379-89. PMC: 3672181. DOI: 10.4161/cbt.23761. View

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi B . Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 2016; 30(1):27-42. DOI: 10.1016/j.ccell.2016.05.004. View

Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C . Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2017; 73(5):751-759. DOI: 10.1016/j.eururo.2017.12.001. View

Li Y, Lin K, Yang Z, Han N, Quan X, Guo X . Bladder cancer stem cells: clonal origin and therapeutic perspectives. Oncotarget. 2017; 8(39):66668-66679. PMC: 5630446. DOI: 10.18632/oncotarget.19112. View

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

Vander Heiden M, Christofk H, Schuman E, Subtelny A, Sharfi H, Harlow E . Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol. 2009; 79(8):1118-24. PMC: 2823991. DOI: 10.1016/j.bcp.2009.12.003. View

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M . Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer. 1997; 76(2):206-10. PMC: 2223948. DOI: 10.1038/bjc.1997.363. View

10.

Lee J, Surh Y . Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 2005; 224(2):171-84. DOI: 10.1016/j.canlet.2004.09.042. View

11.

Yan D, An G, Kuo M . C-Jun N-terminal kinase signalling pathway in response to cisplatin. J Cell Mol Med. 2016; 20(11):2013-2019. PMC: 5082413. DOI: 10.1111/jcmm.12908. View

12.

Wang Y, Hao F, Nan Y, Qu L, Na W, Jia C . PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. Int J Biol Sci. 2018; 14(13):1883-1891. PMC: 6231221. DOI: 10.7150/ijbs.27854. View

13.

Kawashima A, Takayama H, Tsujimura A . A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy. Adv Urol. 2011; 2012:812398. PMC: 3205704. DOI: 10.1155/2012/812398. View

14.

Klatte T, Seitz C, Rink M, Roupret M, Xylinas E, Karakiewicz P . ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. J Urol. 2015; 194(5):1456-62. DOI: 10.1016/j.juro.2015.06.099. View

15.

Mizutani Y, Nakanishi H, Li Y, Sato N, Kawauchi A, Miki T . Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J Urol. 2004; 172(4 Pt 1):1474-9. DOI: 10.1097/01.ju.0000131945.74377.ad. View

16.

Pan X, Hartley J, Hartley J, White K, Wang Z, Bligh S . Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine. 2012; 19(7):618-24. DOI: 10.1016/j.phymed.2012.02.003. View

17.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

18.

Sawant A, Floyd A, Dangeti M, Lei W, Sobol R, Patrick S . Differential role of base excision repair proteins in mediating cisplatin cytotoxicity. DNA Repair (Amst). 2017; 51:46-59. PMC: 5328804. DOI: 10.1016/j.dnarep.2017.01.002. View

19.

Kilari D, Iczkowski K, Pandya C, Robin A, Messing E, Guancial E . Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. Anticancer Res. 2016; 36(2):495-501. View

20.

Zargar H, Zargar-Shoshtari K, Lotan Y, Shah J, van Rhijn B, Daneshmand S . Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?. J Urol. 2015; 195(4 Pt 1):886-93. DOI: 10.1016/j.juro.2015.10.133. View